Meiji Seika Pharma has made an undisclosed sum of strategic investments in French biotechnology firm Osivax in a bid to help accelerate the development of its proprietary universal influenza vaccine candidate OVX836. The pharma arm of Meiji Holdings revealed on…
To read the full story
Related Article
- KM Biologics Bags Option to Osivax’s Universal Flu Vaccines
September 11, 2024
BUSINESS
- Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
- Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
- UK Clears Monthly IV Maintenance Dosing for Leqembi: Eisai/Biogen
November 14, 2025
- Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
November 14, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…





